-transparent.png){kind=logo}
The effects of HCT (0.5 to 1 mg/day subcutaneously), used singly and in combination with a small dose of 1,25-(OH)2D3 (0.25 microgram/day by mouth), have been studied in 16 hemodialysis patients with hypercalcemic hyperparathyroid bone disease for a mean period of 6 months. An intitial improvement occurred in plasma hydroxyproline and hyperparathyroid hormone levels, but there were later rebound increases. There was little overall effect on bone histology, and 10 of the patients had side effects from treatment. HCT in this dose, alone or in combination with small doses of 1,25-(OH)2D3, does not appear to have a major role in the treatment of the hypercalcemic hyperparathyroidism of renal osteodystrophy.
K Farrington, and
Z Varghese, and
J F Moorhead
June 1971,
Canadian Medical Association journal,
K Farrington, and
Z Varghese, and
J F Moorhead
January 1973,
Nephron,
K Farrington, and
Z Varghese, and
J F Moorhead
February 1986,
La Clinica terapeutica,
K Farrington, and
Z Varghese, and
J F Moorhead
May 1977,
The New England journal of medicine,
K Farrington, and
Z Varghese, and
J F Moorhead
September 1985,
La Clinica terapeutica,
K Farrington, and
Z Varghese, and
J F Moorhead
August 1975,
Der Internist,
K Farrington, and
Z Varghese, and
J F Moorhead
November 2000,
Nephron,
K Farrington, and
Z Varghese, and
J F Moorhead
October 1996,
Pediatric nephrology (Berlin, Germany),
K Farrington, and
Z Varghese, and
J F Moorhead
November 1966,
Annals of internal medicine,
K Farrington, and
Z Varghese, and
J F Moorhead
March 1978,
Nederlands tijdschrift voor geneeskunde,
